

Oncolytic Virus Manufacturing

Virus manufacturing for oncolytic therapies

ABL has increased capacity, increased scale, and diversified capabilities to offer a variety of suspension and adherent production platforms to manufacture our clients' novel oncolytic therapies.

Global capabilities include:

- Oncolytic viral vector manufacturing – adherent & suspension platforms:
 - Vaccinia
 - MVA
 - HSV
 - Adenovirus
 - Others
- Aseptic processing for drug substance & drug product
- US- & EU-based GMP operations
- Global supply for Phase I – III & product approval
- Comprehensive QC release & stability testing
- Process & analytical development, qualification, characterization & validation
- 10+ years proven technical & regulatory track record in oncolytic virotherapies





ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France

ABL, Inc. (ABL), a global contract manufacturing organization that advances leading vaccines and therapies from clinical development to the commercial market, is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe SAS (ABL Europe), of a 6,500 m² GMP manufacturing site located in Lyon, France.

[Read More](#)

[Go](#)

Contact us now to speak with one of our experts:

• Name*

First

Last

• Company*

• Email*

• Phone*

• Comments